AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00761124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Session
Description: A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
Study NCT00761124 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Printed Material
Description: General prostate cancer pamphlet
Study NCT01910506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Study NCT03227861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
Description: Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
Study NCT02758145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flu vaccination information in 3 phases
Description: An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated.
Study NCT02325999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD AND LRLD
Description: A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
Study NCT01160367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAILORED Patient Family Decision Making
Description: Patient-family dyads will receive TAILORED intervention on health decision making
Study NCT01160367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Patient-family dyads will receive standard of care in health decision-making
Study NCT05574543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA111
Description: AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Study NCT05574543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Study NCT03540121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video education + adherence contract
Description: Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
Study NCT03366311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: holding position
Description: two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
Study NCT02113722 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Medical therapy
Study NCT02063139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform 50/5 ug (2 puffs bid) pMDI
Study NCT02063139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 50 ug (2puffs bid) pMDI
Study NCT02063139 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beclometasone Autohaler 50 ug (2 puffs bid)
Study NCT04401137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate
Description: Topiramate
Study NCT04401137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate
Study NCT02798081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single arm study
Description: In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
Study NCT01322321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT01322321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01145391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Outreach to Patients and Providers
Description: An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
Study NCT03557372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mathematical Model-Adapted Radiation Fractionation Schedule
Description: * Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~* Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~* Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment.
Study NCT02677740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS (1 Hz)
Description: Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
Study NCT02677740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excitatory rTMS (5 Hz)
Description: Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
Study NCT00244218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tetrahydrobiopterin (BH4)
Description: Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
Study NCT00244218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrobiopterin (BH4)
Description: Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
Study NCT01373554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30mig/bid or 60mg/bid P.O
Study NCT01373554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oltipraz
Description: 30mig/bid or 60mg/bid P.O
Study NCT00135161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
Description: FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
Study NCT00415259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laterally wedged shoe insoles
Description: Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
Study NCT00415259 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control insole group
Description: Flat control insoles worn inside the shoes daily for 12 months
Study NCT03810794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
Study NCT03810794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
Study NCT01116479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Blood transfusion with packed erythrocytes
Study NCT01116479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion with packed erythrocytes
Study NCT02483533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202
Study NCT02483533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03810794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
Study NCT06737510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational brochure on household emergency preparedness
Description: An informational brochure will be mailed to participants and will cover the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies, including preparing a go bag); and (5) resources (including disaster contact numbers for emergency and non-emergency calls (911 and 311), how to register for emergency notifications (Notify NCY), NYC Emergency Management, as well as a website for additional information on preparedness (NYC.gov/hazards) that includes New York City hurricane evacuation zones .
Study NCT06737510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based household emergency preparedness
Description: A phone-based intervention will consist of 15 - 20 minutes discussion covering the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, including a family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies); and (5) resources (including providing NYC Emergency Management website: NYC.gov/hazards, i which includes specific information related to the participants New York City hurricane evacuation zones) .
Study NCT03125356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Soda
Description: Subjects will be asked to consume diet soda three times daily for eight weeks.
Study NCT02576366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Study NCT02576366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study NCT01828307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Description: MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
Study NCT01828307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
Study NCT01828307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Aftercare Treatment
Description: Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
Study NCT03349567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit-and-feedback
Description: We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
Study NCT01828307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Aftercare Treatment
Description: Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
Study NCT03649269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PC-300 tea.
Description: Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
Study NCT03649269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate
Description: Patients were prescribed 200 mg/day at night.
Study NCT04677036 — intervention group
Intervention type: OTHER
Intervention: No intervention is given
Description: No intervention given
Study NCT03041480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid levels and Lp-PLA2
Description: Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
Study NCT03954873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide 2
Description: Human glucagon-like peptide 2
Study NCT00747383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 3mg oral tablet.
Study NCT00747383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg oral tablet.
Study NCT02956525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: Dexibuprofen 200 mg
Study NCT01970566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and Drug
Description: Topiramate-Phentermine plus cognitive behavioral therapy
Study NCT01970566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Intense Exercise/Moderate Calorie Restriction
Study NCT02964611 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational Study
Description: This is an observational study.
Study NCT01970566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: Intense Exercise/Moderate Calorie Restriction
Study NCT01747174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Adenosine
Description: IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
Study NCT01747174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Sodium nitroprusside (SNP)
Description: IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
Study NCT01747174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCI
Description: PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
Study NCT03282331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard oxygenation
Description: Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
Study NCT03282331 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: High flow nasal oxygenation
Description: Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
Study NCT01747174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard PCI
Description: PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
Study NCT04388722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse CO-Oximeter Sensor
Description: Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
Study NCT02404753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
Study NCT02404753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
Study NCT02404753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Laparoscopic distal gastrectomy with D2 lymph node dissection
Study NCT02404753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: Open distal gastrectomy with D2 lymph node dissection
Study NCT02404753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
Study NCT02404753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
Study NCT02490072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
Study NCT03282331 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: noninvasive ventilation
Description: Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
Study NCT03954873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT03954873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 20% (w/v) glucose infusion for regulating plasma glucose
Study NCT02067052 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery, radiotherapy and chemotherapy
Description: Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
Study NCT02067052 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Vulvectomy \& lymphadenectomy
Study NCT02768909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Nose
Description: 1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
Study NCT02768909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Nose
Description: 1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
Study NCT02768909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey & Physical Exam
Description: 2. Perform a oriented survey for risk factors and a complete physical exam.